Pilot Study of GLYLO Supplement Effects on Aging and Metabolic Health in Overweight Postmenopausal Women Aged 45 to 65

What this Trial Is About

Researchers are studying the impact of GLYLO, a dietary supplement, in postmenopausal women aged 45 to 65 who are overweight or obese and have elevated HbA1c levels. The study aims to see if GLYLO can reduce harmful compounds called advanced glycation end products AGEs, improve metabolic and hormonal health, and slow down age-related functional decline. Participants will be randomly assigned to take either GLYLO or a placebo for 24 weeks. The GLYLO group takes one capsule daily for the first week, then two capsules daily from week two onward. The study includes one screening visit and three testing visits over six months, with blood and urine samples collected, physical and cognitive tests performed, and questionnaires completed. During the study, participants will undergo assessments of body measurements, hormone levels, physical performance, and cognitive function. They will use a wearable device to track activity and complete diet questionnaires at the start and end of the study. Compliance is monitored by phone interviews, and safety is assessed throughout. The main outcomes measured are levels of methylglyoxal and AGEs at baseline, 12 weeks, and 24 weeks.

GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women